BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Pembrolizumab: trial readouts and FDA decisions

21 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 32 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Merck Sharp & Dohme LLC, AstraZeneca, GlaxoSmithKline, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Seagen, a wholly owned subsidiary of Pfizer, OncoC4, Inc., Pfizer, Hoffmann-La Roche. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-20 est.P3Merck Sharp & Dohme LLC MRKNCT04634877 Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer Endometrial Neoplasmsactive not recruiting990
2026-12 est.P2Eikon Therapeutics EIKNNCT06246110 A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLCNSCLCactive not recruiting70
2026-12 est.P3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT06711900 A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients WiNon-Small Cell Lung Canceractive not recruiting432
2026-12-10 est.P3Boehringer IngelheimNCT06151574 Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With StandarLung Cancer, Non-squamous, Non-small Cellactive not recruiting428
2026-12-11 est.P2Seagen, a wholly owned subsidiary of PfizerNCT04879329 A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2Urothelial Carcinomarecruiting372
2026-12-14 est.P3Amgen AMGNNCT06430866 Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)active not recruiting163
2026-12-15 est.P1/P2PMV Pharmaceuticals, Inc PMVPNCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung Crecruiting300
2026-12-15 est.P1/P2GV20 TherapeuticsNCT05669430 A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor MalignanciesSolid Tumor, Adult; Refractory Cancer; Endometrial Carcinoma (EC); Squamous Head and Neck Carcinoma;recruiting365
2026-12-31 est.P1/P2OncoC4, Inc.NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCNon Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcactive not recruiting733
2026-12-31 est.P2Innovent Biologics (Suzhou) Co. Ltd.NCT06797297 A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic MucosalMelanomaactive not recruiting203
2027-01 est.P1/P2BicycleTx LimitedNCT04561362 Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced MalignanciesUrinary Bladder Neoplasm; Triple Negative Breast Neoplasms; Hormone Receptor Positive, HER2-negativeactive not recruiting329
2027-01 est.P3AkesoNCT06601335 A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)Head and Neck Squamous Cell Carcinomarecruiting510
2027-01-12 est.P3Merck Sharp & Dohme LLC MRKNCT05609968 Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell LungCarcinoma, Non-Small-Cell Lungactive not recruiting614
2027-01-15 est.P3Regeneron Pharmaceuticals REGNNCT05608291 A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it HasMelanomaactive not recruiting1564
2027-01-15 est.P2/P3IDEAYA Biosciences IDYANCT05987332 IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaMetastatic Uveal Melanomaactive not recruiting420
2027-01-29 est.P3Seagen, a wholly owned subsidiary of PfizerNCT05911295 Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2Urothelial Carcinomaactive not recruiting412
2027-01-30 est.P1/P2Psivac LtdNCT06549946 Ixovex-1 Single Agent and Combination TherapySolid Tumor; Head and Neck Cancerrecruiting18
2027-01-31 est.P3Merck Sharp & Dohme LLC MRKNCT04241185 Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-99Urinary Bladder Neoplasmsactive not recruiting520
2027-02 est.P3Gilead Sciences GILDNCT05382286 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally AdTriple Negative Breast Cancer; PD-L1 Positiveactive not recruiting443
2027-02 est.P1/P2Krystal Biotech, Inc. KRYSNCT06228326 A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the LungsLung Cancer, Non-small Cell; Lung Cancer Metastatic; Solid Tumor, Adult; Advanced Cancer; Lung Cancerecruiting250
2027-02-12 est.P2Merck Sharp & Dohme LLC MRKNCT03407144 Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)Hodgkin Lymphomaactive not recruiting340

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-11 est.P2Precigen, Inc PGENNCT06157151 PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical CancerCervical Cancer; HPV-Related Carcinoma; HPV-Related Malignancy; Recurrent Cervical Carcinoma; Metastrecruiting24
2026-11 est.P3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT06448312 A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerNon-Small Cell Lung Canceractive not recruiting406
2026-10-30 est.P3Pfizer PFENCT04657991 A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic MelanomaMelanomaactive not recruiting257
2026-10-28 est.P3Merck Sharp & Dohme LLC MRKNCT05239728 A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post NephrecCarcinoma, Renal Cellactive not recruiting1800
2026-10-27 est.P2AstraZeneca AZNNCT06008093 A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With ChemotherapCarcinoma, Non-Small-Cell Lungactive not recruiting103
2026-10-26P2GlaxoSmithKlineNCT05565378 A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung CancerLung Cancer, Non-Small Cellactive not recruiting351
2026-10-15P2Hoffmann-La RocheNCT05852691 A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-AdvancedBreast Cancercompleted83
2026-10-05P2Hoffmann-La RocheNCT05805501 A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell CarcinomRenal Cell Carcinomacompleted199
2026-10-01 est.P2Taiho Oncology, Inc.NCT05945823 Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid TumorsLocally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Esophageal Adeactive not recruiting53
2026-10 est.P1/P2Immunocore Ltd IMCRNCT04262466 Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint InhibitorsSelect Advanced Solid Tumorsactive not recruiting410
2026-09-30 est.P2Mirati Therapeutics Inc.NCT05609578 Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C MutationAdvanced NSCLC; Metastatic Lung Canceractive not recruiting90
2026-09-22P1/P2Tango Therapeutics, Inc. TNGXNCT05887492 Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid TumorsNon Small Cell Lung Cancer; Solid Tumors, Adult; Lung Cancer; Lung Adenocarcinomaactive not recruiting126
2026-09-22 est.P1/P2ImmVira Pharma Co. LtdNCT04370587 A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or MeSolid Tumor; Melanoma; HNSCC; Sarcoma; Squamous Cell Carcinoma; NSCLCrecruiting30
2026-09-17P2Arcus Biosciences, Inc. RCUSNCT04736173 Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerNon Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Squamous Non Small Cell Lung Cancompleted169
2026-09-09P1/P2BioInvent International ABNCT06784648 Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic MelanomaMelanoma Metastatic; Melanoma of Skin; Melanoma BRAF V600E/K Mutated; Melanoma Recurrent; Melanoma Sactive not recruiting35
2026-08-31P2Klus Pharma Inc.NCT05816252 A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)Non-small Cell Lung Canceractive not recruiting356
2026-08-30P2OncoC4, Inc.NCT05446298 ONC-392 and Pembrolizumab in Platinum Resistant Ovarian CancerOvarian Cancer; High Grade Serous Adenocarcinoma of Ovary; Primary Peritoneal Carcinoma; Fallopian Tactive not recruiting58
2026-08-25P3PDS Biotechnology Corp. PDSBNCT06790966 Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Cancer; Metastatic Head and Neck Cancer; HPV Positive Oropharyngeal Squamousterminated12
2026-08-17P3AstraZeneca AZNNCT05984277 A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.Metastatic Non-small Cell Lung Canceractive not recruiting895
2026-08-10P1/P2Merck Sharp & Dohme LLC MRKNCT04626479 Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)Carcinoma, Renal Cellcompleted393
2026-07-23P1/P2Merck Sharp & Dohme LLC MRKNCT04626518 Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)Carcinoma, Renal Cellcompleted263
2026-07-13P1/P2GlaxoSmithKlineNCT06405230 Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker PositroLung Cancer, Non-Small Cellterminated2
2026-07-01 est.P1/P2Scancell Ltd SCNLDNCT05329532 Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal CancerTriple Negative Breast Cancer; Renal Cell Cancer; High Grade Ovarian Serous Adenocarcinoma; Squamousrecruiting168
2026-07 est.P1/P2CJ Bioscience, Inc.NCT05877430 Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic CancerNSCLC; HNSCC; Melanoma; Metastatic Cancer; Advanced Solid Tumor; Advanced Cancerrecruiting160
2026-06-30P3GlaxoSmithKlineNCT06472076 A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) HigLung Cancer, Non-Small Cellactive not recruiting88
2026-06-23P1/P2Mirati Therapeutics Inc.NCT03785249 Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1Advanced Cancer; Metastatic Cancer; Malignant Neoplastic Diseaseactive not recruiting731
2026-06-22P1/P2Anaveon AGNCT06470763 A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1)Advanced Solid Tumorcompleted63
2026-06-19P2Pfizer PFENCT05217446 A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic ColorectaMetastatic Colorectal Canceractive not recruiting108
2026-06-17P1/P2Precision Biologics, Inc DTILNCT03476681 Study of NEO-201 in Solid Tumors Expansion CohortsNon Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Cervical Cancer; Uterine Canceractive not recruiting121
2026-06-09P3AstraZeneca AZNNCT05048797 A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small CLocally Advanced or Metastatic Non-Small Cell Lung Canceractive not recruiting454
2026-06-08P2Merck Sharp & Dohme LLC MRKNCT04123366 Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous ReSolid Tumorscompleted333
2026-06 est.P1/P21ST Biotherapeutics, Inc.NCT05761223 A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849Advanced Solid Tumorrecruiting151

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.